These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 18498105)

  • 1. Pepsinogen-like activation intermediate of plasmepsin II revealed by molecular dynamics analysis.
    Friedman R; Caflisch A
    Proteins; 2008 Dec; 73(4):814-27. PubMed ID: 18498105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The protonation state of the catalytic aspartates in plasmepsin II.
    Friedman R; Caflisch A
    FEBS Lett; 2007 Aug; 581(21):4120-4. PubMed ID: 17689534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crystal structure of the novel aspartic proteinase zymogen proplasmepsin II from plasmodium falciparum.
    Bernstein NK; Cherney MM; Loetscher H; Ridley RG; James MN
    Nat Struct Biol; 1999 Jan; 6(1):32-7. PubMed ID: 9886289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prosegment catalyzes native folding of Plasmodium falciparum plasmepsin II.
    Jaafar AH; Xiao H; Dee DR; Bryksa BC; Bhaumik P; Yada RY
    Biochim Biophys Acta; 2016 Oct; 1864(10):1356-62. PubMed ID: 27378574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Computational analysis of plasmepsin IV bound to an allophenylnorstatine inhibitor.
    Gutiérrez-de-Terán H; Nervall M; Dunn BM; Clemente JC; Aqvist J
    FEBS Lett; 2006 Oct; 580(25):5910-6. PubMed ID: 17045991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting functional residues in Plasmodium falciparum plasmepsins by combining sequence and structural analysis with molecular dynamics simulations.
    Valiente PA; Batista PR; Pupo A; Pons T; Valencia A; Pascutti PG
    Proteins; 2008 Nov; 73(2):440-57. PubMed ID: 18442137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dissection of the pH dependence of inhibitor binding energetics for an aspartic protease: direct measurement of the protonation states of the catalytic aspartic acid residues.
    Xie D; Gulnik S; Collins L; Gustchina E; Suvorov L; Erickson JW
    Biochemistry; 1997 Dec; 36(51):16166-72. PubMed ID: 9405050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. On the orientation of the catalytic dyad in aspartic proteases.
    Friedman R; Caflisch A
    Proteins; 2010 May; 78(6):1575-82. PubMed ID: 20112416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural insights into the activation of P. vivax plasmepsin.
    Bernstein NK; Cherney MM; Yowell CA; Dame JB; James MN
    J Mol Biol; 2003 Jun; 329(3):505-24. PubMed ID: 12767832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular dynamics simulations of the three dimensional model of plasmepsin II-peptidic inhibitor complexes.
    Pranav Kumar SK; Kulkarni VM
    Drug Des Discov; 2001; 17(4):293-313. PubMed ID: 11765133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potent inhibitors of the Plasmodium falciparum enzymes plasmepsin I and II devoid of cathepsin D inhibitory activity.
    Ersmark K; Feierberg I; Bjelic S; Hamelink E; Hackett F; Blackman MJ; Hultén J; Samuelsson B; Aqvist J; Hallberg A
    J Med Chem; 2004 Jan; 47(1):110-22. PubMed ID: 14695825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Crystallographic evidence for noncoplanar catalytic aspartic acids in plasmepsin II resides in the Protein Data Bank.
    Robbins AH; Dunn BM; Agbandje-McKenna M; McKenna R
    Acta Crystallogr D Biol Crystallogr; 2009 Mar; 65(Pt 3):294-6. PubMed ID: 19237752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Flap flexibility amongst plasmepsins I, II, III, IV, and V: Sequence, structural, and molecular dynamics analyses.
    McGillewie L; Soliman ME
    Proteins; 2015 Sep; 83(9):1693-705. PubMed ID: 26146842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pyrrolidine derivatives as plasmepsin inhibitors: binding mode analysis assisted by molecular dynamics simulations of a highly flexible protein.
    Luksch T; Blum A; Klee N; Diederich WE; Sotriffer CA; Klebe G
    ChemMedChem; 2010 Mar; 5(3):443-54. PubMed ID: 20112327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural and active site analysis of plasmepsins of Plasmodium falciparum: potential anti-malarial targets.
    Bhargavi R; Sastry GM; Murty US; Sastry GN
    Int J Biol Macromol; 2005 Oct; 37(1-2):73-84. PubMed ID: 16242183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Catalysis and linear free energy relationships in aspartic proteases.
    Bjelic S; Aqvist J
    Biochemistry; 2006 Jun; 45(25):7709-23. PubMed ID: 16784222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New organofluorine building blocks: inhibition of the malarial aspartic proteases plasmepsin II and IV by alicyclic alpha,alpha-difluoroketone hydrates.
    Fäh C; Hardegger LA; Baitsch L; Schweizer WB; Meyer S; Bur D; Diederich F
    Org Biomol Chem; 2009 Oct; 7(19):3947-57. PubMed ID: 19763297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression and characterisation of plasmepsin I from Plasmodium falciparum.
    Moon RP; Tyas L; Certa U; Rupp K; Bur D; Jacquet C; Matile H; Loetscher H; Grueninger-Leitch F; Kay J; Dunn BM; Berry C; Ridley RG
    Eur J Biochem; 1997 Mar; 244(2):552-60. PubMed ID: 9119023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural aspects of activation pathways of aspartic protease zymogens and viral 3C protease precursors.
    Khan AR; Khazanovich-Bernstein N; Bergmann EM; James MN
    Proc Natl Acad Sci U S A; 1999 Sep; 96(20):10968-75. PubMed ID: 10500110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of plasmepsin inhibitors by fragment-based docking and consensus scoring.
    Friedman R; Caflisch A
    ChemMedChem; 2009 Aug; 4(8):1317-26. PubMed ID: 19472268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.